肝细胞癌伴门静脉癌栓放射治疗进展

摘要/Abstract

摘要： 肝细胞癌（HCC）伴门静脉癌栓（PVTT）患者病情发展迅速,预后差,严重危及患者生命。目前HCC伴PVTT可选择的治疗方式主要有经肝动脉介入治疗、放射治疗（简称放疗）、靶向治疗、免疫治疗、手术等,但尚无标准治疗方案。调强放疗可显著提高肿瘤剂量,同时可以更好地保护剩余肝,保证了肝癌放疗的安全性,临床研究的结果也证实了HCC伴PVTT放疗是安全有效的。随着多学科治疗理念的深入,放疗联合多种治疗手段逐渐应用于HCC伴PVTT患者的治疗中。本文主要以HCC伴PVTT的放疗为中心,探讨放疗与手术、介入治疗、靶向治疗、免疫治疗等多学科联合治疗的进展。

关键词: 肝细胞癌, 门静脉癌栓, 放射治疗

Abstract: With a poor prognosis, hepatocellular carcinoma (HCC) with portal vein tumor thrombus (PVTT) progresses rapidly and is life-threatening. Currently, the treatment options for HCC with PVTT mainly include transcatheter arterial intervention, radiotherapy, targeted therapy, immunotherapy, surgery, etc., but there is still no standard treatment strategy. Intensity-modulated radiotherapy can significantly raise the prescribed dose with the minimum dose delivery to the remaining liver, ensuring the safety of radiotherapy for HCC. Previous clinical studies have confirmed the safety and efficacy of radiotherapy for HCC with PVTT. With the deepening of the multidisciplinary treatment concept, radiotherapy combined with other treatments for HCC with PVTT has been continuously explored. Focusing on radiotherapy for HCC with PVTT, this review mainly discusses the progress of multidisciplinary combined therapy including radiotherapy, surgery, interventional therapy, targeted therapy, and immunotherapy.

Key words: Hepatocellular carcinoma, Portal vein tumor thrombus, Radiotherapy

辛玲霞, 许新, 翟医蕊, 邓敏, 陈波. 肝细胞癌伴门静脉癌栓放射治疗进展[J]. 肝癌电子杂志, 2023, 10(3): 76-82.

Xin Lingxia, Xu Xin, Zhai Yirui, Deng Min, Chen Bo. The progress of radiotherapy in hepatocellular carcinoma with portal vein tumor thrombus[J]. Electronic Journal of Liver Tumor, 2023, 10(3): 76-82.

参考文献

[1] ZHENG R, ZHANG S, ZENG H, et al.Cancer incidence and mortality in China, 2016[J]. J Nat Cancer Center, 2022, 2(1): 1-9.
[2] SUNG H, FERLAY J, SIEGEL R L, et al.Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2021, 71(3): 209-249.
[3] CHENG S, CHEN M, CAI J, et al.Chinese expert consensus on multidisciplinary diagnosis and treatment of hepatocellular carcinoma with portal vein tumor thrombus (2018 edition)[J]. Liver Cancer, 2020, 9(1): 28-40.
[4] CHENG S, CHEN M, CAI J.Chinese expert consensus on multidisciplinary diagnosis and treatment of hepatocellular carcinoma with portal vein tumor thrombus: 2016 edition[J]. Oncotarget, 2017, 8(5): 8867-8876.
[5] KHAN A R, WEI X, XU X.Portal vein tumor thrombosis and hepatocellular carcinoma - the changing tides[J]. J Hepatocell Carcinoma, 2021, 8: 1089-1115.
[6] EASL Clinical practice guidelines: management of hepatocellular carcinoma[J]. J Hepatol, 2018, 69(1): 182-236.
[7] LUO F, LI M, DING J, et al.The progress in the treatment of hepatocellular carcinoma with portal vein tumor thrombus[J]. Front Oncol, 2021, 11: 635731.
[8] SCHöNIGER-HEKELE M, MüLLER C, KUTILEK M, et al. Hepatocellular carcinoma in Central Europe: prognostic features and survival[J]. Gut, 2001, 48(1): 103-109.
[9] GIANNINI E G, BUCCI L, GARUTI F, et al.Patients with advanced hepatocellular carcinoma need a personalized management: A lesson from clinical practice[J]. Hepatology, 2018, 67(5): 1784-1796.
[10] SHI J, LAI E C, LI N, et al.A new classification for hepatocellular carcinoma with portal vein tumor thrombus[J]. J Hepatobiliary Pancreat Sci, 2011, 18(1): 74-80.
[11] 中华人民共和国国家卫生健康委员会. 原发性肝癌诊疗指南(2022年版)[J/CD ]. 肿瘤综合治疗电子杂志,2022,8(2):16-53.
[12] 全国肝癌合并癌栓诊治研究协作组. 肝细胞癌合并门静脉癌栓多学科诊治中国专家共识(2016年版) [J/CD]. 肝癌电子杂志, 2018, 5(2): 1-7.
[13] REIG M, FORNER A, RIMOLA J, et al.BCLC strategy for prognosis prediction and treatment recommendation: the 2022 update[J]. J Hepatol, 2022, 76(3): 681-693.
[14] BREDER V V. IMbrave150: Exploratory efficacy and safety results of hepatocellular carcinoma (HCC) patients (pts) with main trunk and/or contralateral portal vein invasion (Vp4) treated with atezolizumab (atezo) + bevacizumab (bev) versus sorafenib (sor) in a global Phase III study [Z].2021 ASCO Abs 4073. 2021
[15] KONYN P, AHMED A, KIM D.Current epidemiology in hepatocellular carcinoma[J]. Expert Rev Gastroenterol Hepatol, 2021, 15(11): 1295-1307.
[16] SON S H, JANG H S, LEE H, et al.Determination of the α/β ratio for the normal liver on the basis of radiation-induced hepatic toxicities in patients with hepatocellular carcinoma[J]. Radiat Oncol, 2013, 8: 61.
[17] TAI A, ERICKSON B, KHATER K A, et al.Estimate of radiobiologic parameters from clinical data for biologically based treatment planning for liver irradiation[J]. Int J Radiat Oncol Biol Phys, 2008, 70(3): 900-907.
[18] CHEN C P.Role of External Beam Radiotherapy in Hepatocellular Carcinoma[J]. Clin Liver Dis, 2020, 24(4): 701-717.
[19] KLEIN J, DAWSON L A.Hepatocellular carcinoma radiation therapy: review of evidence and future opportunities[J]. Int J Radiat Oncol Biol Phys, 2013, 87(1): 22-32.
[20] IKAI I, YAMAMOTO Y, YAMAMOTO N, et al. Results of hepatic resection for hepatocellular carcinoma invading major portal and/or hepatic veins [J]. Surg Oncol Clin N Am, 2003, 12(1): 65-75, ix.
[21] SHI J, LAI E C, LI N, et al.Surgical treatment of hepatocellular carcinoma with portal vein tumor thrombus[J]. Ann Surg Oncol, 2010, 17(8): 2073-2080.
[22] CHEN Y, GRASSBERGER C, LI J, et al.Impact of potentially variable RBE in liver proton therapy[J]. Phys Med Biol, 2018, 63(19): 195001.
[23] ZENG Z C, JIANG G L, WANG G M, et al.DNA-PKcs subunits in radiosensitization by hyperthermia on hepatocellular carcinoma hepG2 cell line[J]. World J Gastroenterol, 2002, 8(5): 797-803.
[24] TAI A, ERICKSON B, LI X A.Extrapolation of normal tissue complication probability for different fractionations in liver irradiation[J]. Int J Radiat Oncol Biol Phys, 2009, 74(1): 283-289.
[25] 张龙. 肝癌门静脉癌栓放射治疗敏感性研究[D].北京:中国科学院大学,2015.
[26] DAYAL R, SINGH A, PANDEY A, et al.Reactive oxygen species as mediator of tumor radiosensitivity[J]. J Cancer Res Ther, 2014, 10(4): 811-818.
[27] CHEN B, LI Y X, WANG L, et al.Phase II study of concurrent sorafenib and radiotherapy for advanced hepatocellular carcinoma with portal vein and/or hepatic vein tumor thrombosis[J]. Int J Radiat Oncol Biol Phys, 2021, 111(3 Suppl): S39.
[28] LEE J H, KIM D H, KI Y K, et al.Three-dimensional conformal radiotherapy for portal vein tumor thrombosis alone in advanced hepatocellular carcinoma[J]. Radiat Oncol J, 2014, 32(3): 170-178.
[29] KIM D Y, PARK W, LIM D H, et al.Three-dimensional conformal radiotherapy for portal vein thrombosis of hepatocellular carcinoma[J]. Cancer, 2005, 103(11): 2419-2426.
[30] ZENG Z C, FAN J, TANG Z Y, et al.A comparison of treatment combinations with and without radiotherapy for hepatocellular carcinoma with portal vein and/or inferior vena cava tumor thrombus[J]. Int J Radiat Oncol Biol Phys, 2005, 61(2): 432-443.
[31] NAKAZAWA T, HIDAKA H, SHIBUYA A, et al.Overall survival in response to sorafenib versus radiotherapy in unresectable hepatocellular carcinoma with major portal vein tumor thrombosis: propensity score analysis[J]. BMC Gastroenterol, 2014, 14: 84.
[32] IKAI I, KUDO M, ARII S, et al.Report of the 18th follow-up survey of primary liver cancer in Japan[J]. Hepatol Res, 2010, 40(11): 1043-1059.
[33] BAI T, CHEN J, XIE Z B, et al.The efficacy and safety of postoperative adjuvant transarterial embolization and radiotherapy in hepatocellular carcinoma patients with portal vein tumor thrombus[J]. Onco Targets Ther, 2016, 9: 3841-3848.
[34] SUN J, YANG L, SHI J, et al.Postoperative adjuvant IMRT for patients with HCC and portal vein tumor thrombus: An open-label randomized controlled trial[J]. Radiother Oncol, 2019, 140: 20-25.
[35] KAMIYAMA T, NAKANISHI K, YOKOO H, et al.Efficacy of preoperative radiotherapy to portal vein tumor thrombus in the main trunk or first branch in patients with hepatocellular carcinoma[J]. Int J Clin Oncol, 2007, 12(5): 363-368.
[36] LI N, FENG S, XUE J, et al.Hepatocellular carcinoma with main portal vein tumor thrombus: a comparative study comparing hepatectomy with or without neoadjuvant radiotherapy[J]. HPB (Oxford), 2016, 18(6): 549-556.
[37] WEI X, JIANG Y, ZHANG X, et al.Neoadjuvant three-dimensional conformal radiotherapy for resectable hepatocellular carcinoma with portal vein tumor thrombus: a randomized, open-label, multicenter controlled study[J]. J Clin Oncol, 2019, 37(24): 2141-2151.
[38] SILVA J P, BERGER N G, TSAI S, et al.Transarterial chemoembolization in hepatocellular carcinoma with portal vein tumor thrombosis: a systematic review and meta-analysis[J]. HPB (Oxford), 2017, 19(8): 659-666.
[39] CHUNG G E, LEE J H, KIM H Y, et al.Transarterial chemoembolization can be safely performed in patients with hepatocellular carcinoma invading the main portal vein and may improve the overall survival[J]. Radiology, 2011, 258(2): 627-634.
[40] HUO Y R, ESLICK G D.Transcatheter arterial chemoembolization plus radiotherapy compared with chemoembolization alone for hepatocellular carcinoma: a systematic review and Meta-analysis[J]. JAMA Oncol, 2015, 1(6): 756-765.
[41] YOON S M, LIM Y S, WON H J, et al.Radiotherapy plus transarterial chemoembolization for hepatocellular carcinoma invading the portal vein: long-term patient outcomes[J]. Int J Radiat Oncol Biol Phys, 2012, 82(5): 2004-2011.
[42] LU D H, FEI Z L, ZHOU J P, et al.A comparison between three-dimensional conformal radiotherapy combined with interventional treatment and interventional treatment alone for hepatocellular carcinoma with portal vein tumour thrombosis[J]. J Med Imaging Radiat Oncol, 2015, 59(1): 109-114.
[43] YOON S M, RYOO B Y, LEE S J, et al.Efficacy and safety of transarterial chemoembolization plus external beam radiotherapy vs sorafenib in hepatocellular carcinoma with macroscopic vascular invasion: a randomized clinical trial[J]. JAMA Oncol, 2018, 4(5): 661-669.
[44] CHEN B, LI Y X, WANG W, et al.Efficacy and prognosis of radiotherapy for hepatocellular carcinoma with tumor thrombosis in main portal vein or/and vena cava[J]. Int J Radiat Oncol Biol Phys, 2019, 105(1 Suppl): E215-E6.
[45] ZHAO Y, ZHU X, WANG H, et al.Safety and efficacy of transcatheter arterial chemoembolization plus radiotherapy combined with sorafenib in hepatocellular carcinoma showing macrovascular invasion[J]. Front Oncol, 2019, 9: 1065.
[46] SONG D S, SONG M J, BAE S H, et al.A comparative study between sorafenib and hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma with portal vein tumor thrombosis[J]. J Gastroenterol, 2015, 50(4): 445-454.
[47] CHOI J H, CHUNG W J, BAE S H, et al.Randomized, prospective, comparative study on the effects and safety of sorafenib ∶hepatic arterial infusion chemotherapy in patients with advanced hepatocellular carcinoma with portal vein tumor thrombosis[J]. Cancer Chemother Pharmacol,2018,82(3):469-478.
[48] LYU N, LIN Y, KONG Y, et al.FOXAI: a phase II trial evaluating the efficacy and safety of hepatic arterial infusion of oxaliplatin plus fluorouracil/leucovorin for advanced hepatocellular carcinoma[J]. Gut, 2018, 67(2): 395-396.
[49] KONDO M, MORIMOTO M, KOBAYASHI S, et al.Randomized, phase II trial of sequential hepatic arterial infusion chemotherapy and sorafenib versus sorafenib alone as initial therapy for advanced hepatocellular carcinoma: SCOOP-2 trial[J]. BMC Cancer, 2019, 19(1): 954.
[50] LYU N, KONG Y, MU L, et al.Hepatic arterial infusion of oxaliplatin plus fluorouracil/leucovorin:sorafenib for advanced hepatocellular carcinoma[J]. J Hepatol, 2018, 69(1): 60-69.
[51] IKEDA M, SHIMIZU S, SATO T, et al.Sorafenib plus hepatic arterial infusion chemotherapy with cisplatin versus sorafenib for advanced hepatocellular carcinoma: randomized phase II trial[J]. Ann Oncol, 2016, 27(11): 2090-2096.
[52] HE M, LI Q, ZOU R, et al.Sorafenib plus hepatic arterial infusion of oxaliplatin, fluorouracil, and leucovorin vs sorafenib alone for hepatocellular carcinoma with portal vein invasion: a randomized clinical trial[J]. JAMA Oncol, 2019, 5(7): 953-960.
[53] KUDO M, UESHIMA K, YOKOSUKA O, et al.Sorafenib plus low-dose cisplatin and fluorouracil hepatic arterial infusion chemotherapy versus sorafenib alone in patients with advanced hepatocellular carcinoma (SILIUS): a randomised, open label, phase 3 trial[J]. Lancet Gastroenterol Hepatol,2018,3(6): 424-432.
[54] FUJINO H, KIMURA T, AIKATA H, et al.Role of 3-D conformal radiotherapy for major portal vein tumor thrombosis combined with hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma[J]. Hepatol Res, 2015, 45(6): 607-617.
[55] KODAMA K, KAWAOKA T, AIKATA H, et al.Comparison of outcome of hepatic arterial infusion chemotherapy combined with radiotherapy and sorafenib for advanced hepatocellular carcinoma patients with major portal vein tumor thrombosis[J]. Oncology, 2018, 94(4): 215-222.
[56] SU F, CHEN K H, LIANG Z G, et al.Comparison of three-dimensional conformal radiotherapy and hepatic resection in hepatocellular carcinoma with portal vein tumor thrombus[J]. Cancer Med, 2018, 7(9): 4387-4395.
[57] LEE Y H, TAI D, YIP C, et al.Combinational immunotherapy for hepatocellular carcinoma: radiotherapy, immune checkpoint blockade and beyond[J]. Front Immunol, 2020, 11: 568759.
[58] ABULIMITI M, LI Z, WANG H, et al.Combination intensity-modulated radiotherapy and sorafenib improves outcomes in hepatocellular carcinoma with portal vein tumor thrombosis[J]. J Oncol, 2021, 2021: 9943683.
[59] QUE J, WU H C, LIN C H, et al.Comparison of stereotactic body radiation therapy with and without sorafenib as treatment for hepatocellular carcinoma with portal vein tumor thrombosis[J]. Medicine (Baltimore), 2020, 99(13): e19660.
[60] BOUSTANI J, GRAPIN M, LAURENT P A, et al.The 6th R of radiobiology: reactivation of anti-tumor immune response[J]. Cancers (Basel), 2019, 11(6):860.
[61] APETOH L, GHIRINGHELLI F, TESNIERE A, et al.Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy[J]. Nat Med, 2007, 13(9): 1050-1059.
[62] REITS E A, HODGE J W, HERBERTS C A, et al.Radiation modulates the peptide repertoire, enhances MHC class I expression, and induces successful antitumor immunotherapy[J]. J Exp Med, 2006, 203(5): 1259-1271.
[63] JIANG W, CHAN C K, WEISSMAN I L, et al.Immune priming of the tumor microenvironment by radiation[J]. Trends Cancer, 2016, 2(11): 638-645.
[64] DOVEDI S J, ADLARD A L, LIPOWSKA-BHALLA G, et al.Acquired resistance to fractionated radiotherapy can be overcome by concurrent PD-L1 blockade[J]. Cancer Res, 2014, 74(19): 5458-5468.
[65] REYNDERS K, ILLIDGE T, SIVA S, et al.The abscopal effect of local radiotherapy: using immunotherapy to make a rare event clinically relevant[J]. Cancer Treat Rev, 2015, 41(6): 503-510.
[66] 郑宣陈, 李晔雄. 肝细胞肝癌放疗联合免疫治疗研究进展[J/CD]. 肝癌电子杂志, 2019, 6(4): 5-8.
[67] CHEN B, ZHAI Y R, LI Y X, et al.Previous/concurrent radiation enhanced the response of toripalimab in advanced and recurrent liver cancer: a pilot study[J]. Int J Radiat Oncol Biol Phys, 2021, 111(3 Suppl): e34.